Reproductive BioMedicine Online
Volume 21, Issue 7 , Pages 830-833, December 2010

The moral status of the embryo: an attempt at an analysis with the aid of David Hume’s ethics

Received 15 April 2010; received in revised form 30 June 2010; accepted 6 July 2010. published online 02 August 2010.

Declaration: The authors report no financial or commercial conflicts of interest.

Abstract 

This article applies the moral sentimentalism founded by David Hume to the moral status of the embryo. It will attempt to explain the paradoxical fact that in Germany abortion is common and socially accepted while preimplantation genetic diagnosis is banned with the aid of an approach based on moral sentimentalism. David Hume established the thesis that the human being is guided by the emotions and not by reason when making moral decisions. Scientific innovations often create a feeling of anxiety. Consequently, the initial moral judgment about it is negative. Due to this habit, the innovation is often accepted after a phase of indifference. This phenomenon has been observed in the case of heart transplantation, as well as for IVF. Consequently, the apparent contradiction in the varying degrees of the embryo’s worthiness of protection in the womb and in the Petri dish is due to the simple fact that these are different stages of habituation. Therefore, the ethics of Hume cannot stipulate the embryo’s moral status for once and for all; however, they can paradoxically raise the ongoing current debate to a more rational level through the insight that the underlying moral concepts are not based on reason alone.

The ethics of moral sentimentalism, based on the reflections of David Hume (1711–1767), a Scottish philosopher of the age of enlightenment, are applied to the moral status of the embryo. The fact that abortion is socially accepted in Germany while at the same time preimplantation genetic diagnosis (PGD) is forbidden represents a paradox is explained by the ethical concept of moral sentimentalism. Hume observed that moral reflections and decisions in humans are rather driven by passions than by reason. This speculative concept is supported by recently published neuroimaging studies. Scientific innovations are often seen with distrust because of modern myths such as Huxley’s Brave New World. Also, our Christian background causes a special sensitivity towards science concerning the beginnings of life and, because of Germany’s history, genetic testing has a negative connotation. Thus, a scientific innovation, such as PGD, frequently induces a vague feeling of anxiety. Accordingly, such new methods are at first morally rejected by the majority. However, by sheer force of habit these innovations are frequently met with indifference and finally morally approved in the course of time. This development is observed in different areas of medicine. Therefore, the different moral value of the embryo in the uterus and in the Petri dish are based on different stages of moral adaption and cannot be established as a fixed constant by moral sentimentalism. Clarifying that our moral judgement is not based exclusively on reason and rationality can, however, raise the ongoing debate to a more rational level.

Keywords: David Hume, ethics, moral sentimentalism, preimplantation genetic diagnosis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Jörg Bernhard Engel, born 18 October 1972, studied medicine at University of Göttingen, Germany until 2000. From January 2001, he undertook an internship at the Department of Gynecology and Obstetrics, University Clinic Hospital Schleswig-Holstein. From August 2002, he worked at Hôpital Antoine Béclère, Paris, France. From April 2003, he worked as a research fellow at the Endocrine, Polypeptide and Cancer Institute at Tulane University Medical School, New Orleans, USA. From April 2005, he undertook his residency in the Department of Obstetrics and Gynecology, University of Würzburg, Germany and he obtained a position as attending physician in this department in December 2008.

PII: S1472-6483(10)00457-8

doi:10.1016/j.rbmo.2010.07.003

Reproductive BioMedicine Online
Volume 21, Issue 7 , Pages 830-833, December 2010